Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs such as aminolevulinic acid are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells.
PURPOSE: Randomized phase II trial to study the effectiveness of photodynamic therapy using aminolevulinic acid in treating patients who have cutaneous T-cell lymphoma, B-cell lymphoma, or early chronic lymphocytic leukemia involving the skin.
| Condition | Intervention | Phase |
|---|---|---|
|
Leukemia Lymphoma |
Drug: aminolevulinic acid hydrochloride |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | A Pilot Study of Short (1-2.5 h), Medium (4-6 h) and Long (18-24 h) Applications of 20% Topical ALA-PDT for Photodynamic Therapy of Cutaneous T and B Cell Lymphomas and Cutaneous Infiltrates of Early CLL |
- Pain grade and epidermal toxic response (ETR) [ Designated as safety issue: Yes ]
- Feasibility of maintaining a pain grade of 1 or less and an approximate ETR of 2 [ Designated as safety issue: No ]
- Maximal irradiance and corresponding exposure [ Designated as safety issue: No ]
- Cumulative response achieved at the completion of treatment [ Designated as safety issue: No ]
- Number of sessions required to complete treatment [ Designated as safety issue: No ]
- Correlation of ETR with incremental treatment response [ Designated as safety issue: No ]
| Enrollment: | 1 |
| Study Start Date: | February 1999 |
| Primary Completion Date: | July 2005 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine the pain grade and epidermal toxic response (ETR) of patients with T-cell or B-cell lymphoma or early chronic lymphocytic leukemia with cutaneous infiltrates treated with photodynamic therapy using aminolevulinic acid.
- Determine the feasibility of maintaining a pain grade of 1 or less and an approximate ETR of 2 in patients receiving up to 12 sessions of this regimen.
- Determine the maximal irradiance and corresponding exposure among multiple treatments at the same site and among different sites in the same and in different patients.
- Determine the cumulative response achieved at the completion of treatment in these patients.
- Determine the number of sessions required to complete treatment in these patients.
- Correlate ETR with incremental treatment response in patients treated with this regimen.
OUTLINE: This is a randomized study. Patients' individual lesions are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive a short duration of topical aminolevulinic acid (ALA) on the lesion and surrounding normal skin. The lesion is then illuminated with red light for up to 30 minutes.
- Arm II: Patients receive a medium duration of ALA followed by light illumination as in arm I.
- Arm III: Patients receive a long duration of ALA followed by light illumination as in arm I.
In all arms, treatment repeats every 2 weeks for up to 12 courses in the absence of unacceptable toxicity or progressive (systemic) disease.
Additional patients are accrued to a treatment arm if at least 2 of 3 patients on that arm experience 25% cumulative clinical response.
Patients are followed at 1, 3, and 6 months and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 4-10 patients will be accrued for this study within 5-7 years.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
One of the following histologically confirmed diagnoses:
Cutaneous B-cell or T-cell lymphoma confined to the skin
- No evidence of internal disease other than peripheral adenopathy
- Early chronic lymphocytic leukemia with cutaneous B-cell infiltrates not requiring systemic therapy
- Stable or slowly progressive disease that is not expected to substantially change during treatment
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Not pregnant or nursing
- No porphyria or known hypersensitivity to porphyrins
- No known photosensitivity diseases
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Concurrent clinically necessary interferon alfa allowed
Chemotherapy
- No concurrent systemic multiagent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No concurrent local radiotherapy to study lesions
- No concurrent whole body radiotherapy
Surgery
- Not specified
Other
- More than 1 month since prior topical therapy to study lesions
- Concurrent topical therapy to non-study lesions allowed
Contacts and Locations| United States, New York | |
| Roswell Park Cancer Institute | |
| Buffalo, New York, United States, 14263-0001 | |
| Study Chair: | Allan R. Oseroff, MD, PhD | Roswell Park Cancer Institute |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00054171 History of Changes |
| Other Study ID Numbers: | DS 97-32, RPCI-DS-9732 |
| Study First Received: | February 5, 2003 |
| Last Updated: | January 30, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Roswell Park Cancer Institute:
|
B-cell chronic lymphocytic leukemia stage I cutaneous T-cell non-Hodgkin lymphoma stage I mycosis fungoides/Sezary syndrome stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphoma Neoplasms by Histologic Type Neoplasms Leukemia, B-Cell Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Aminolevulinic Acid Photosensitizing Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions Dermatologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013